SMMT
NASDAQ · Biotechnology
Summit Therapeutics Inc
$15.54
-0.06 (-0.38%)
Financial Highlights (FY 2025)
Revenue
1.10B
Net Income
169.72M
Gross Margin
31.1%
Profit Margin
15.4%
Rev Growth
-3.6%
D/E Ratio
1.16
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 31.1% | 31.1% | 31.1% |
| Operating Margin | 19.2% | 19.5% | 19.2% |
| Profit Margin | 15.4% | 15.6% | 16.1% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.10B | 1.08B | 883.89M |
| Gross Profit | 342.43M | 337.02M | 275.00M |
| Operating Income | 211.18M | 211.72M | 169.61M |
| Net Income | 169.72M | 168.86M | 142.65M |
| Gross Margin | 31.1% | 31.1% | 31.1% |
| Operating Margin | 19.2% | 19.5% | 19.2% |
| Profit Margin | 15.4% | 15.6% | 16.1% |
| Rev Growth | -3.6% | +10.5% | -9.8% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 5.18B | 5.03B | 5.42B |
| Total Equity | 4.48B | 4.78B | 4.60B |
| D/E Ratio | 1.16 | 1.05 | 1.18 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 286.46M | 306.19M | 235.37M |
| Free Cash Flow | 170.10M | 157.58M | 108.43M |